These data, along with more detailed correlative studies defining the prognostic and predictive value of CD39 expression on the full range of distinct cell types within the tumor microenvironment will provide important insights into CD39 as a clinically relevant therapeutic target. The gene discussed is ENTPD1; the disease is neoplasm.